

References

- Akyol Mu , Sarac S, Akyol G , Atac A , Poyraz A , Belgin E , And Turan E.(2001) :** Investigation of the ototoxic effects of interferon α 2A on the mouse cochlea . Otolaryngol Head and Neck Surgery ; 124:107 -110.
- Al Faleh FZ, RamiaS, ArifM, AyoolaEA , Al RashedRS , al Jeffry M, HossainA , ,and El- HazamiM. (1995):**profile of hepatitis c virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia : a community based study. Ann Trop Med parasitol ; 89: 431-437 .
- Alter MJKruszon-Moran DNainanOV , McQuillanGM , GaoF , Moyer LA , Kaslow RA , and Margolis HS. (1999) :** the prevalence of hepatitis c virus infection in the united states , 1988 through 1994.N Engl J Med ; Aug 19 ; 341 : 556-562 .
- American Speech Language-Hearing Association (ASHA) (1994):**Guidelines for the audiologic management of individuals receiving cochleo-toxic drug therapy. ASHA, 36 (supp1.12):11-19.
- Amin J, GiddingH, Gilbert G , Backhouse J , KaldorJ , Dore G , and Burgess M . (2004) :** hepatitis C prevalence a nationwide sero-survey. commun Dis Intel ; 28 (4) : 517-521.

- Angelico M , RenganathanE, GandinCG,Fathy M, ProfiliMC, Refai W , De Santis A, Nagi A, Amin G, CapocacciaL, CalleaF, RapicettaM , BadrG, and Rocchi G . (1997) :** chronic liver disease in the Alexandria governorate , Egypt : contribution of schistosomiasis and hepatitis virus infections. *J. Hepatol* ; 26:236- 431.
- ApichartpiyakulC,ApichartpiyakulN,NrwijitaroonY, Gray J, NatpratanC , Katayama Y, FujiiM, and HottaH . (1999) :**sero-prevalence and subtype distribution of hepatitis C virus among blood donors and intravenous drug users in northern/ northeastern Thailand. *Jpn J Infect Dis .Jun* : 52(3) : 121-123.
- ArafaN, El HoseinyM, RekacewiczC, Bark I, El KafrawyS, El Daly M, AounS, MarzoukD , Mohamed MK , and FontanetA. (2005) :**changing pattern of hepatitis C virus spread in rural areas of Egypt .*J Hepatol*: 43(3) : 418- 424.
- Atug O,Akin H,Yilmaz Y, Sari M, Tozun N. (2009):**Pegylated interferon/ribavirin-induced sudden .sensorineural hearing loss in a patient with chronic hepatitis C. *J Gastrointestin Liver Dis*;18:256,2009.
- BarnaTK, OzsvarZ, SzendrenyiV, and Gal G. (1996):**hepatitis C virus antibody in the serum of blood donors. *OrvosiHetilap*; 137:507-511
- BartenschlagerR, and LohmannV. (2000):**Replication of hepatitis C virus; *J of General Virology*; 81: 1631-1648.

- Bassily S, Hyams KC, Fouad RA, Samaan MD, and Hibbs RG. (1995):** A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse. *Aam JTrop Med Hyg.* 52(6):503-505.
- Bayer N, Bake Bapan A, and Cankoas M. (2001):** Efficacy of topotecan treatment on experimental model of transient evoked Otoacoustic emissions. *Int j pediater Otorhinolaryngol.* nov, 61;135-142.
- Beardsley AM, LaBrooy JT, Rozen L, and Gowans EJ. (1994):** A comparison of hepatitis C virus (HCV) RNA and antibody as markers of infection and predictors of infectivity. *Aust NZJ Med;* 24:182-187.
- Beck A, Maurer J, Welkoborsky H, and mann W. (1992) :** changes in transient evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU. *H No,* 40(4);123-127
- Beld M, penning M, McMorrow M, Gorgels J, Van den Hoek A, and Goudsmit J. (1998) :** Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine amino-transferase levels. *J Clin Microbion;* 36:872-877.
- Bellentani S, and Tiribelli C. (2001) :** the spectrum of liver disease in the general population: lesson from the Dionysos study. *J Hepatol;* 35: 531-537.

Brownell ,WE, Bader CR, Bertrand D, and Ribanpierre Y. (1985): evoked mechanical responses of isolated outer hair cells. *Science*; 227:194-196.

CadoniG, MarinelliL, De SantisA, Romito A, Manna R, and Ottaviani F.(1998): Sudden hearing loss in a patient hepatitis C virus positive on therapy with interferon alfa: a possible autoimmune-microvascular pathogenesis. *J LaryngolOtol*; 112:962-963.

Campbell KC, and Durrant J. (1993) :Audiologic monitoring for ototoxicity . *OtoryngolClin North Am* 1993 .Oct ; 26 (5) : 903-914

Chung A, and Older SA.(1997): Interferon-alpha associated arthritis . *J. Rheumatol.* 24, pp. 1844-1845 .

Cohen S. (2007): Chronic Hepatitis. *The Merck Manual of Medical Information- Second home edition WWW at:* <<http://www.merck.com/mmhe/sec10/ch137/ch137c.html>>

Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, and Trepo C.(2001): Sensitivity and specificity of third generation hepatitis C virus antibody detection assays : an analysis of the literature . *J Viral Hepat.*Mar ; 8(2) : 87-95

- Cox AL, Netski DM, Mosbrugger T, Sherman SG, Strathedee S, OmpadD, Vlahov D, Chien D, Shyamala V, Ray SC, and Thomas DL.(2005):** prospective evaluation of community acquired acute phase hepatitis C virus infection . Clin Infect Dis; 40(7):951-958
- DarwishNM, Abbas MO, AbdelfattahFM, and DarwishMA.(1992):** Hepatitis C virus infection in blood donors in Egypt. J Egypt public Health Assoc, 67(34): 223-236.
- Darwish MA, Raouf TA, Rushdy P, Constantine NT, Rao MR, and Edelman R. (1993) :** risk factors associated with a high seroprevalence of hepatitis c virus infection inegyption blood donors. am j trop med hyg ; 49(4):440-447.
- Deleersnyder V, pillez A, Wychowski C, Blight K, Xu J, Hahn YS, Rice CM, and Dubuissson J.(1997) :** Formation of native hepatitis C virus glycoprotein complexes . J of Virology; 71:697-704.
- DiagoM, CastellanoG, Garcia-Samaniego J, Perez C, Fernandez I, Romero M, Lacono OL, and Garcia-Monzon C. (2006):** Association of pretreatment serum interferon {gamma} inducible protein 10 levels with sustained virological response to peg-interferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 55:374-379.

- Diedrich G, (2006):** How does hepatitis C virus enter cells?
FEBS J: 3781-3885.
- Dreschler WA, Van der Hulst RJ, Tange RA, and Urbanus NA.(1989):** Role of high frequency audiometry in the early detection of ototoxicity . II. Clinical Aspects :28(4) :211-220.
- DusheikoG(1997).** Side effect of alpha interferon in chronic hepatitis C. Hepatology 1997;26(suppl.):112-21.
- Elloumi H, Houissa F, HadjNB, Gargouri D, Romani M, Kharrat J, and Ghorble A. (2007):** Sudden hearing loss associated with peg interferon and ribavirin combination therapy during hepatitis C treatment World . Oct 28; 13(40): 5411-412.
- El-Zayadi A, Simmonds P, Dabbous H, and Prescott L, SelimO, and AhdyA.(1996):** Response to interferon α of Egyptian patients infected with hepatitis C virus genotype 4.J. Viral hepatitis ; 3: 261-264.
- European Association for the study of liver diseases (EASL) International Consensus Conference on Hepatitis C. (1999):** consensus statement ; J of hepatology, 31: 3-8.
- Fanning L, (2000):** natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology; 31: 225-229.
- Fausti S, Larson V, Noffsinger D, Wilson R, Phillips D, and Fowler C. (1994):** high frequency audiometric monitoring

strategies for early detection of ototoxicity. *Ear and Hearing*; 15 (3): 232-239.

Favre D, Berthillon P, and Trepo C.(2001): Removal of cell bound lipoproteins: a crucial step for the efficient infection of liver cells with hepatitis C virus in vitro. *C R AcadSci III*; (324): 1141-1148.

Feld JJ andHoofnagle JH.(2005):Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* 2005;436:967-72.

FormannE, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, Gangl A, and Ferenci P. (2004): Sudden hearing loss in patient with hepatitis C treated with pegylated interferon/ribavirin. *Am j Gastroenterol*; 99:873-877.

Franciscus A, and Highleyman L. (2006a): Hepatitis C virus treatment consideration; In: *A Guide to Understanding Hepatitis C*; franciscus A, and Highleyman L. (Editors); a publication of hepatitis C support project (HCVSP); San Francisco, California : e-published in WWW page at: <http://www.hcvadvocate.org>>, last updated on 2006.

Franciscus A, and Highleyman L.(2006b): Hepatitis C virus medications side effects management; In: *A guide to Understanding Hepatitis C*; franciscus A, and Highleyman L. (Editors) ; a publication of hepatitis C support project (HCVSP) ; San Francisco, California : e-published in

WWW page at: <http://www.hcvadvocate.org>, last updated on 2006.

Frank C , Mohamed MK , Strickland GT , Lavanchy D , Arthur RR, Magder LS, EL Khoby T, Abdel-Wahab Y , AlyOhn ES, Anwar W, and Sallam I. (2002): The role of parenteral anti-schistosomal therapy in the spread of Hepatitis C virus in Egypt ; lancet; 355 : 887 – 891.

Fried MW, (2002): side effects of Therapy of Hepatitis C and Their Management; Hepatology, Vol. 36, No. 5, Suppl. 1, S237-S244.

Frolenkov GI, Belyansteva IA, Kurc M, Mastroianni MA, and Kachar B.(1998): Cochlear outer hair cell electromotility can provide force for both low and high intensity distortion product otoacoustic emissions .Hear Res; Dec; 126 (1): 67-74.

Gish RG. (2006):Treating HCV with ribavirin analogues and ribavirin like molecules. J Antimicrobial chemotherapy 57(1): 8-13.

Glynn SA, Wright DJ, Kleinman SH , Hirschkoran D , Tu Y , Heldebrant C, Smith R , Giachetti C , Gallarda J and Busch M. (2005): Dynamics of viremia in early hepatitis C virus infection . Transfusion; 45(6) : 994- 1002.

- Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, and Wilber LC. (1998):** sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. *Hepatology*; 28: 1702-1706.
- Görür K, Kandemirö, Unal M, and Ozcan C. (2003):** the effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B; *AurisNasus Larynx*, Volume 30, Issue 1, 15 February , pages 41- 44.
- Güneri EA, Serbeteioğlu B, İkiz AO, Güneri A, and Ceryan K. (2001):** Transient evoked otoacoustic emissions monitoring of cisplatin induced ototoxicity in guinea pigs : the protective effect of vitamin B treatment .*AurisNasus Larynx* Jan; 28 (1): 9-14.
- Halfon P, Bourliere M, Halimi G, Khiri H, Bertezene P, Portal I, BottaFridlund D, Gauthier AP, Jullien M, Feryn JM, Gerolami V, and Cartouzou G, (1998) :** assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor Monitor. *J ClinMicrobiol*; 36: 2073 - 2075.
- Hoofnagle JH, and Seeff LB. (2006):** Peginterferon and Ribavirin for Chronic Hepatitis C. *The New England J of medicine*, December 7: 2444-2451.

- Ilako FM, McLigeyo SO, Riyat MS, Lule GN, Okoth FA, and Kaptich D. (1995):** The prevalence of hepatitis C virus antibodies in renal patients, blood donors and patients with chronic liver disease in Kenya. *East Afr Med J*; 72:362-364.
- Jamal M, and Theodore S. (2006):** Epidemiology of hepatitis C virus (HCV) infection *Int J Med Sci*. April; 3(2) :41- 46.
- Johnson K, Sargent LA, Galizio C, Ubogu EE.(2008):** Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. *Eur J GastroenterolHepatol* 2008;20:1110-4.
- Kakigi A, Hirakawa H, Hard N, Mount RJ, and Harrison RV. (1998):** Comparison of distortion product otoacoustic emissions and transient evoked otoacoustic emissions threshold shift in chinchillas with ototoxic damage. *AurisNasusLarynx*; Sep 25:223- 232.
- Kamal SM, Madwar MA, Peters T, Fawzy R, and Rasenack J. (2000):** Interferon therapy in patients with chronic hepatitis C and schistosomiasis. *J. Hepatol* . 32: 172-174.
- kandaY, Shigeno K, Kinoshita N, Nakao K, Yano M, and Matsuo H. (1994):** Sudden hearing loss associated with interferon. *Lancet*; 343: 1134-1135.
- Kanda Y, Shigeno K, and Matsuo H, Yano M, Yamada N, Kumagami H.(1995):** Interferon induced hearing loss; *Audiology*; 34:98-102.

- Katbamna B, Homnick DN, Marks JH.(1999)** Effects of chronic tobramycin treatment on distortion product otoacoustic emissions. *Ear hear* 1999;20:393-402.
- Kemp DT. (1978):** Stimulated acoustic emissions from within the human auditory system . *J AcoustSoc Am*; 64: 1386 - 1391.
- KhannaSM, and Leonard DG.(1986):** relationship between basilar membrane tuning and hair cell condition. *Hear Res* 1986; 23:55-70.
- Lemon SM, and Brown EA. (1995):** Hepatitis C virus. In: Mandell GL, Bennett JE, Dolin R, eds. *Principle and practice of infectious disease*, Fourth edition. New York, Churchill Livingstone, 1474-1486.
- Lohmann V, Korner F, Koch JO, Herian U, Theilmann L, and Bartenschlager R. (1999):** Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line; *science*; 285, 110-113.
- Lorenz, R.R., Solares, C.A., Williams, P., Sikora, J., Pelfrey, C.M., et al. (2002).** Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss. *JNeuroimmunol*, 130, 173_8.
- Maruyama S, Hirayama C, Kadowaki Y, Sagayama A, Omura H, Nakamoto M.(1998):** Interferon-induced anosmia in a patient with chronic hepatitis C. *Am J Gastroenterol* 1998;93:122-3.

- Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, and Alter MJ. (2005):** Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis.* Dec 1; 192(11): 1880-1889.
- McCarthy MC , EL Tigani A, Khalid IO, and Hyams KC.(1994) :** Hepatitis B and C in Juba , southern Sudan: results of a sero-survey.*Trans. Roy; Soc. Trop. Med. Hyg;* 88:534-536.
- Mohamed MK, Abdel Hamid M, Mikhail NN, Abdel Aziz F, MedhatA, Magder LS, Fix AD,and Strickland GT. (2005):** Intrafamilial transmission of hepatitis C in Egypt. *Hepatology*; 42:683-687.
- Mosley JW,Operskalski EA, Tobler LH, Andrews WW, Phelps B Dockter J, Giachetti C, and Busch MP. (2005):** Viral and host factors in early hepatitis C virus infection .*Hepatology* ; 42(1) :86-92.
- Moyer LA, Mast EE, and Alter MJ. (1999):** Hepatitis C : part II. Prevention Counselling and Medical Evaluation: American Academy of Family Physicians WWW page at: http://WWW.aafp.org/afp/990115ap_/349.html>, created: 09/00; reviewed / updated: 06/06.
- Muhammad N, and Jan MA. (2005):**Frequencey of Hepatitis C in Buner, NWFP. *J Coll Physicians Surg Park.*; 15(1) :11 -14.

- Mukherjee S, and Dhawan VK.(2009):** Hepatitis C; WWW pages at:<[http:// emedicine. medscape.com/article/177792-overview](http://emedicine.medscape.com/article/177792-overview)> , last updated on Jun 18, 2009.
- Mulheran M, andDegg C.(1997)** Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. *Br J Audiol* 1997;31:5-9.
- Nagy J, Adelstien D, newman C, Rybicki L, Rice T, and Lavertu P.(1999):**Cisplatin ototoxicity: the importance of baseline audiometry. *Am J ClinOncol*; 22 (3): 305-308.
- Norton S, and Stover L.(1994):**Otoacousticemissions:An emerging clinical tool. In: Katz J. (Ed) *Handbook of clinical audiology* fourth ed. Williams and Wilkins. Ch., 29, p: 448-462.
- Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y,Tada H, Sawa Y, Mizuno M, Kagawa K, and Kashima K.(1996):**Side effects of high-dose interferon therapy for chronic hepatitis C; *J Hepatology*; (25); 3: 283-291.
- Orts AM, Garcia CJ, Morant VA, Ferrer BF, Esparcia NM, and Marco AJ. (2000):**Clinical study on the ototoxicity of cisplatin with distortion products. *Actaotorhinolaryngol Esp. Aug-Sep*; 51(6) :469-477.

- Ozturan O, Jerger J, Lew H, and Lynch G.(1996):**Monitoring of cisplatin ototoxicity by distortion product otoacoustic emission .*AurisNasus larynx*, 23:147-151.
- Pawlotsky, JM, Bouvier-Alias, M, Hezode, C, Darthuy , F, Remire, J and Dhumeaux , D. (2000):** Standardization of hepatitis C virus (HCV) RNA quantification . *Hepatology* 32, pp. 654-659.
- Pawlotsky JM. (2002):**Use and interpretation of virological tests for hepatitis C, *Hepatology* ; 36: 65-73.
- PiekarskaA, JozefowiczKorczynska M, WojcikK, and Berkan E (2007):** Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin; *Int J Audiol* Jul; 46 (7) :345-350.
- Pradat P, Caillat-vallet, Sahajian F, Bailly F, Excler G, Sepetjan M, Trepo C, FabryJ, and ADHEC members (2001):** Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. *Eur J Epidemiol*; 17 (1): 47-51.
- ProbstR, Coats A, Martian G, and Lonsbury Martin B. (1986):**
Spontaneous, click and tone burst, evoked otoacousticemmissions from normal ears. *Hear Res*; 21: 261-275.

- Probst R, Lonsbury Martian B, and Martin G. (1991):** A review of otoacoustic emissions . J Acoust Soc Am 89, 2027-2067.
- Proceedings of the International Workshop on Epidemiology. (1996):** diagnosis and management of hepatitis C infection, USA.
- Purcell RH (1994):** Hepatitis C virus. In: Webster RG, Granoff A, (eds.) Second Edition, Encyclopedia of Virology. London, Academic Press Ltd: 657-663.
- Pybus OG, Drummond AJ, Nakano T, Robertson BH, and Rambaut A. (2003):** The Epidemiology and Iatrogenic Transmission of hepatitis C virus in Egypt : a Bayesian Coalescent Approach. Molecular Biology Evaluation; 20(3): 381-387.
- Quinti I, Renganathan E, El Ghazzawi E, Divizia M, Sawaf G, Awad S, Pana A, and Rocchi G. (1995)** : seroprevalence of HIV and HCV infection in Alexandria, Egypt. Zentralbl. Bakteriologie; 283: 239-244.
- Ramia S, and Eid Fares J. (2006):** Distribution of hepatitis C virus genotypes in the Middle East. International J of infectious diseases; 10:272-277.
- Rao MR, Naficy AB, Darwish MA, Darwish NM, Schisterman E, Clemens JD, and Edelman R. (2002):** Further evidence for association of hepatitis C infection

- with parenteral schistosomiasis treatment in Egypt BMC Infectious diseases; 2 (29): 1-7.
- Ray SC, Arthur RR, Carella A, BukhJ, and Thomas DL.(2000):** epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis; 182: 698-707.
- RolandT, and Cohen J. (1998):** Vestibular and auditory ototoxicity. In: Otolaryngology head and neck surgery , Cummings C.W. (Ed); 3rd edition, Mosby year book. St. Louis, Vol. E, Chapter 164.
- RybakL, and Matz G. (1993):** Effects of ototoxic agents. In: Cumming C. (ed.): Otolaryngology head and neck surgery, Mosby year book, St; Lious, 2ndEd , chapter 165:2943-2964.
- Shobokshi OA, Serebour F, Skakni L, Al Saffy Y, and Ahdal M. (1998):** Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol; 58: 44 - 48.
- Sokalingam R, Freeman S, Cherny L, and Sohmer H. (2000):** Effect of high dose cisplatin on ABR and OAEs in laboratory animals . Am J Otol Jul; 21(4);310- 314.
- Stavroulaki P, Apostolopoulos N, Dinopoulou D, Vossinakis I, Tsakanikos M, and Douniadakis D. (1999):**Otoacoustic emissions – an approach for monitoring aminoglycoside induced ototoxicity in children. Int. J pediaterhinolaryngol; Nov 5; 50(3) :177-184.

- Stavroulaki P, Apostolopoulos N, Segas J, Tsukanikos M. (2001):** Evoked Otoacoustic emissions- an approach for monitoring cisplatin induced ototoxicity in children. *Int J PediatrOtorhinolaryngol*; May 31; 59 (1) : 47 – 57.
- Strickland GT. (2006):**Liver Disease in Egypt: Hepatitis C Superseded schistosomiasis as a result of Iatrogenic and Biological Factors. *Hepatology*; 43: 915 -922.
- Tanaka J, KumagaiJ, Katayama K, Komiya Y, Mizui M, Yamanaka R, Suzuki K, Miyakawa Y, and Yoshizawa H. (2004):** Sex and age specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3, 485, 748 first time blood donors during 1995- 2000. *intervirology* ; 47(1) : 32- 40.
- Tang S. (1993):**Sero-epidemiological study on hepatitis C virus infection among blood donors from various regions in China. *Chin J Epidemiol*; 14: 271 -274.
- Taylor DR, Shi ST, Romano PR, Barber GN and Lai MC. (1999):**Inhibition of the interferon inducible protein kinase PKR by HCV E2 protein; *Science*; 285, 107 -110.
- Thimme R , Oldach D, Change KM, SteigerC, Ray SC, andChisari FV.(2001):** Determinants of viral clearance and persistence during acute hepatitis C virus infection . *J Exp Med*; 194 (10): 1395 -1406.
- Toosi MN, and Hassanabadi MS. (2004):**Hearing Loss as a complication of peg-interferon alfa 2a complication

therapy in a patient with hepatitis C virus infection; hepatitis monthly; 4 (7) 79 – 82.

Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F , Coppola RC, Sauleda S, Thursz MR, Tillmann H, Alberti A, Braconier JH, Esteban JI, Hadziyannis SJ, Manns MP , Saracco G, Thomas HC, and Trepo C. (2000): Epidemiology of hepatitis C virus infection in seven european union countries : a critical analysis of the literature ; Hencore Group (Hepatitis C European Network for Cooperative Research); Eur J GastroenterolHepatol; 12 : 667 -668.

Tunca A, Erbayrak M, Aytac S, and Turay C. (2004): Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B : A case report. Turk J Gastroenterol; 15: 97-99.

Van Damme P, Thyssen A, and Van Loock F. (2002): Epidemiology of hepstitis C in Belgium : present and future. ActaGsatroenterolBelg; 65: 78- 79.

Voisset C, Callens N, Blanchard E, De Beeck EO, Dubuisson J, and Vu Dac N.(2005):High dinesity lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B e type I . J.Biol. Chem. 280: 30705 – 30711.

Walker CM. (1999): Hepatitis C virus. In: Ahmed R, Chen I, eds. Persistent Viral Infections. Chichester, Wiley: 93-115.

Wang Y, Tao QM, , Zhao HY, Tsuda F, Nagayama R, Yamamoto K, Tanaka T, Tokita H , Okamoto H, and Miyakawa Y. (1994): Hepatitis C virus RAN and antibodies among blood donors in Beijing; J Hepatol. Oct; 21(4): 634 – 640.

Wejstal R. (1999): Sexual transmission of hepatitis C virus; Journal of Hepatology, 31: 92- 95.

Wong VK, Cheong-lee C, Ford JA, and Yoshida EM. (2005): Acute sensorineural hearing loss associated with peg-interferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy World. Sep. 14; 11(34): 5392-5393.

Woo HM, and Burnakis TG. (1997): Interferon alpha in treatment of chronic hepatitis C and B; Ann pharcother; 31: 330- 337.

World Health Organization (WHO) (1997): Hepatitis C : global prevalence ; weekly epidemiological record; 72: 341 -344.

World Health Organization (WHO) (2003): Hepatitis C. WWW page at: < http: //WWW.who.int/csr/disease/hepatitis/>

World Health Organization (WHO) (2006): Hepatitis C. Fact Sheet No. 164 , 2000 Available in WWW page at : <<http://www.who.int/mediacentre/factsheets/fs164/en/>>;accessed 31 August.

- Yamada E, Montoya M, Schuettler CG, Hickling TP, Tarr AW, Vitelli A, Dubuisson J, Patel AH, Ball JK, and Borrow P. (2005):** Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mono nuclear cell subsets; *J Gen Virol*; Sep; 86: 2507 -2512.
- Youssef AM. (1998):** Transient evoked otoacoustic emission as an early marker of functional deficit in the cochlea in ototoxicity; *El- Menia Med Bull* vol. no. 1 Jan, 210 -218.
- Yu H, Huang H, Xiang J, Babiuk LA, Van Drunen Little – van den Hurk S. (2006):** Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3; *J Gen Virol* ; Jan; 87 : 1-10
- Zanetti AR, Tanzi E, and Newell ML. (1999):** Mother to infant transmission of hepatitis C virus. *J of Hepatology*, 31: 96-100.